{"transactions":[{"id":2095646,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":121851,"kind":"person","name":"Sabus Steve M","position":1,"cik":"0001930884","reported_name":"Sabus Steve M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2022-12-05T21:41:39.000Z","date":"2022-12-05","kind":"grant","acquired":true,"shares":220000,"price":25.44,"value":5596800.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty five percent (25%) of the total number of shares underlying the option shall vest on December 5, 2023, and one-thirty-sixth (1/36th) of the remaining shares underlying the option shall vest monthly thereafter on the last day of each month, subject to the reporting person's continuous service on the relevant vesting dates."}],"balance_after":220000,"derivative":{"exercise_price":25.44,"expiration_date":"2032-12-05","underlying":"Common Stock","underlying_shares":220000},"source":{"system":"sec-edgar","filing":"0001562180-22-008056","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022008056/primarydocument.xml","form_type":"4"}},{"id":2180671,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":121851,"kind":"person","name":"Sabus Steve M","position":1,"cik":"0001930884","reported_name":"Sabus Steve M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-08-17T16:27:59.000Z","date":"2022-08-17","kind":"disposition_to_issuer","acquired":false,"shares":165000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law."}],"balance_after":0,"derivative":{"exercise_price":35.37,"expiration_date":"2032-05-30","underlying":"Common Stock","underlying_shares":165000},"source":{"system":"sec-edgar","filing":"0001209191-22-046268","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1595893/000120919122046268/doc4.xml","form_type":"4"}},{"id":2180670,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":121851,"kind":"person","name":"Sabus Steve M","position":1,"cik":"0001930884","reported_name":"Sabus Steve M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-08-17T16:27:59.000Z","date":"2022-08-17","kind":"disposition_to_issuer","acquired":false,"shares":36667,"price":76,"value":2786692.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the \"Issuer\"), Bristol-Myers Squibb Company (\"BMS\") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS (\"Purchaser\"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for $76.00 per Share in cash, without interest, subject to any applicable withholding of taxes (the \"Cash Amount\"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Cash Amount."},{"field":"shares","element":"transactionShares","label":"F2","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding restricted stock unit award (\"RSU\") whether vested or unvested was cancelled and converted into the right to receive cash, without interest, in an amount equal to $76.00 per Share issuable in settlement of such RSU immediately before the effective time of the Merger, net of any withholding taxes required to be deducted and withheld by applicable law."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-22-046268","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1595893/000120919122046268/doc4.xml","form_type":"4"}},{"id":2249062,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":121851,"kind":"person","name":"Sabus Steve M","position":1,"cik":"0001930884","reported_name":"Sabus Steve M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-06-01T17:02:36.000Z","date":"2022-05-31","kind":"grant","acquired":true,"shares":165000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares vest on May 31, 2023 and 1/48th of the shares vest monthly thereafter over the next three years."}],"balance_after":165000,"derivative":{"exercise_price":35.37,"expiration_date":"2032-05-30","underlying":"Common Stock","underlying_shares":165000},"source":{"system":"sec-edgar","filing":"0001209191-22-033207","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1595893/000120919122033207/doc4.xml","form_type":"4"}},{"id":2249061,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":121851,"kind":"person","name":"Sabus Steve M","position":1,"cik":"0001930884","reported_name":"Sabus Steve M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-06-01T17:02:36.000Z","date":"2022-05-31","kind":"grant","acquired":true,"shares":36667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit award granted under the Issuer's 2019 Equity Incentive Plan."}],"balance_after":36667,"source":{"system":"sec-edgar","filing":"0001209191-22-033207","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1595893/000120919122033207/doc4.xml","form_type":"4"}}]}